BioAge Labs (NASDAQ:BIOA) Upgraded to Hold at UBS Group

UBS Group upgraded shares of BioAge Labs (NASDAQ:BIOA) to a hold rating in a research note released on Sunday,Zacks reports.

A number of other equities analysts also recently issued reports on the company. Wall Street Zen downgraded BioAge Labs from a “sell” rating to a “strong sell” rating in a research note on Saturday. Roth Capital reissued a “buy” rating and issued a $25.00 price objective on shares of BioAge Labs in a research note on Wednesday, September 9th. Needham & Company LLC dropped their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a report on Friday, July 31st. Finally, Weiss Ratings cut BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $33.00.

BioAge Labs Trading Down 6.2%

BIOA opened at $5.57 on Friday. BioAge Labs has a 1-year low of $5.04 and a 1-year high of $25.95. The company has a market cap of $255.66 million, a price-to-earnings ratio of -2.34 and a beta of 1.08. The company’s fifty day moving average price is $8.75 and its two-hundred day moving average price is $15.39.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The company had revenue of $2.45 million during the quarter. As a group, equities analysts forecast that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of BioAge Labs during the 2nd quarter valued at $69,831,000. Jupiter Topco LLC purchased a new position in shares of BioAge Labs in the 2nd quarter worth about $52,597,000. Janus Henderson Group PLC boosted its holdings in shares of BioAge Labs by 411.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP grew its position in BioAge Labs by 9.4% during the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after buying an additional 150,000 shares during the period. Finally, Walleye Capital LLC bought a new position in BioAge Labs during the second quarter valued at about $8,686,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.